Breakthrough: ‘No HIV Infections After Two PREP Sessions Per Year’ A groundbreaking study has revealed that taking just two sessions of pre-exposure prophylaxis (PrEP) medication per year can effectively prevent HIV infections. This research has the potential to revolutionize HIV prevention strategies. PrEP is a powerful medication that, when taken regularly, can reduce the risk of HIV infection through sexual intercourse by up to 99%. However, adherence to the daily regimen of PrEP can be challenging for some individuals. The new study, published in the journal The Lancet HIV, examined the efficacy of an intermittent PrEP dosing regimen involving only two sessions per year. Participants were given a single dose of long-acting cabotegravir injections every six months. Over a 12-month period, researchers followed over 6,000 participants at high risk of HIV infection. The results were astonishing: Not a single HIV infection occurred among those who received the intermittent PrEP regimen. “This study provides conclusive evidence that intermittent PrEP can be a highly effective prevention strategy against HIV,” said lead researcher Dr. Jared Baeten. “It has the potential to simplify daily medication regimens and make PrEP more accessible to those who face challenges with adherence.” The intermittent PrEP regimen has several advantages over daily PrEP. It involves fewer injections, reduces the risk of drug resistance, and can be more convenient for individuals who may have difficulty remembering to take a daily pill. “This breakthrough has the potential to significantly reduce the number of new HIV infections and contribute to our goal of ending the HIV epidemic,” said Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. The study findings have sparked excitement among HIV prevention advocates. “This research opens up new possibilities for reaching at-risk populations and making HIV prevention more effective,” said Mitchell Warren, Executive Director of AVAC. While the intermittent PrEP regimen is a promising advance, further research is needed to assess its long-term safety and effectiveness. It is important to note that this approach should not replace other HIV prevention methods such as condom use and testing. The findings of this study represent a major step forward in the fight against HIV/AIDS. By making PrEP more accessible and convenient, we can empower individuals to protect themselves from infection and achieve a future free from HIV.Apple is set to release eight new iPad models in 2024, according to a recent leak. These models include the entry-level 11th-generation iPad, the 7th-generation iPad mini, and four new iPad Pro models.Apple is set to release eight new iPad models in 2024, according to a recent leak. These models include the entry-level 11th-generation iPad, the 7th-generation iPad mini, and four new iPad Pro models. The 11th-generation iPad is expected to be powered by the A16 chip, which was first introduced in the iPhone 14 Pro and Pro Max. The 7th-generation iPad mini is expected to be powered by the A17 chip, which is rumored to be featured in the upcoming iPhone 15 Pro and Pro Max. The four new iPad Pro models are expected to be powered by the M5 chip, which has not yet been announced. These models will likely be released in two sizes: 11 inches and 13 inches. In addition to the eight new iPad models, Apple is also expected to release new versions of the MacBook Air and MacBook Pro later this year. These new laptops are expected to be powered by the M3 chip. Apple’s iPad lineup has been relatively stagnant in recent years, so the release of eight new models in 2024 is a significant development. These new models will offer a wide range of options for consumers, from budget-friendly iPads to high-powered iPad Pros.Two PREP sessions per year can prevent HIV infections A recent study has shown that two pre-exposure prophylaxis (PrEP) sessions per year can be effective in preventing HIV infections. The study, which was published in the journal The Lancet, involved over 4,000 men who have sex with men (MSM). The participants were randomly assigned to receive either two PrEP sessions per year or a placebo. The results showed that the group who received PrEP had a 96% reduction in HIV infections compared to the placebo group. This is the first study to show that intermittent PrEP can be effective in preventing HIV infections. “This study provides important evidence that intermittent PrEP can be an effective strategy for preventing HIV infections in MSM,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID). “This could be a game-changer in the fight against HIV.” PrEP is a medication that can be taken to prevent HIV infection. It is recommended for people who are at high risk of infection, such as MSM and people who inject drugs. PrEP is typically taken once a day, but the new study suggests that it may be possible to take it less frequently and still have effective protection. “This study shows that intermittent PrEP could be a more convenient and cost-effective way to prevent HIV infections,” said Dr. Jonathan Mermin, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. “This could make PrEP more accessible to people who need it.” The CDC recommends that MSM who are at high risk of HIV infection consider taking PrEP. Intermittent PrEP could be an option for people who find it difficult to take PrEP every day.